C4 Therapeutics, Inc. (NASDAQ: CCCC) reported Q1 EPS of ($0.37), $0.09 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $7.24 million versus the consensus estimate of $4.74 million.

For earnings history and earnings-related data on C4 Therapeutics, Inc. (CCCC) click here.